{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:47:41Z","timestamp":1783702061244,"version":"3.55.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011851","name":"Kom op tegen Kanker","doi-asserted-by":"publisher","award":["3M220408"],"award-info":[{"award-number":["3M220408"]}],"id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["I001420N"],"award-info":[{"award-number":["I001420N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030780","name":"Wetenschappelijk Fonds Willy Gepts, Universitair Ziekenhuis Brussel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004418","name":"Vrije Universiteit Brussel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004418","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.canlet.2026.218245","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:19:31Z","timestamp":1767831571000},"page":"218245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The clinically available supplement pyruvate enhances the therapeutic effect of bortezomib in Multiple Myeloma by modulating mitochondrial metabolism"],"prefix":"10.1016","volume":"640","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9281-5298","authenticated-orcid":false,"given":"Chenggong","family":"Tu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0345-721X","authenticated-orcid":false,"given":"Arne","family":"Van der Vreken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Faict","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze","family":"Ates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8418-5879","authenticated-orcid":false,"given":"Ann","family":"Massie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1313-6121","authenticated-orcid":false,"given":"Kim","family":"De Veirman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"De Bruyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Vanderkerken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0805-6581","authenticated-orcid":false,"given":"Eline","family":"Menu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.canlet.2026.218245_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"17","key":"10.1016\/j.canlet.2026.218245_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174082","article-title":"Multiple myeloma therapy: emerging trends and challenges","volume":"14","author":"Dima","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.canlet.2026.218245_bib3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40164-024-00535-1","article-title":"Fueling CARs: metabolic strategies to enhance CAR T-cell therapy","volume":"13","author":"Van der Vreken","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2026.218245_bib4","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","article-title":"Proteasome inhibitors in multiple myeloma: 10 years later","volume":"120","author":"Moreau","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.canlet.2026.218245_bib5","doi-asserted-by":"crossref","first-page":"C451","DOI":"10.1152\/ajpcell.00286.2019","article-title":"Proteasome inhibition in multiple myeloma: lessons for other cancers","volume":"318","author":"Saavedra-Garcia","year":"2020","journal-title":"Am. J. Physiol.: Cell Physiol."},{"issue":"36","key":"10.1016\/j.canlet.2026.218245_bib6","doi-asserted-by":"crossref","first-page":"33714","DOI":"10.1074\/jbc.M302559200","article-title":"Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells","volume":"278","author":"Ling","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.canlet.2026.218245_bib7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","article-title":"The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status","volume":"107","author":"Perez-Galan","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.canlet.2026.218245_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cells9112357","article-title":"ROS overproduction sensitises myeloma cells to bortezomib-induced apoptosis and alleviates tumour microenvironment-mediated cell resistance","volume":"9","author":"Caillot","year":"2020","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.canlet.2026.218245_bib9","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1007\/s00018-021-03756-3","article-title":"Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma","volume":"78","author":"Xiong","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"issue":"10","key":"10.1016\/j.canlet.2026.218245_bib10","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.15252\/embr.201642195","article-title":"The integrated stress response","volume":"17","author":"Pakos-Zebrucka","year":"2016","journal-title":"EMBO Rep."},{"issue":"8065","key":"10.1016\/j.canlet.2026.218245_bib11","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/s41586-025-08794-6","article-title":"Plasticity of the mammalian integrated stress response","volume":"641","author":"Chen","year":"2025","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.canlet.2026.218245_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107151","article-title":"The integrated stress response in metabolic adaptation","volume":"300","author":"Ryoo","year":"2024","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2026.218245_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.747837","article-title":"Targeting the integrated stress response in cancer therapy","volume":"12","author":"Tian","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218245_bib14","article-title":"Minimal residual disease assessment in multiple myeloma patients: minimal disease with maximal implications","volume":"11","author":"Charalampous","year":"2021","journal-title":"Front. Oncol."},{"issue":"14","key":"10.1016\/j.canlet.2026.218245_bib15","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1182\/bloodadvances.2022008345","article-title":"The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma","volume":"7","author":"Findlay","year":"2023","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.canlet.2026.218245_bib16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.mito.2007.07.002","article-title":"Therapeutic potential of pyruvate therapy for mitochondrial diseases","volume":"7","author":"Tanaka","year":"2007","journal-title":"Mitochondrion"},{"issue":"14","key":"10.1016\/j.canlet.2026.218245_bib17","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1007\/s00018-013-1539-2","article-title":"Regulation of pyruvate metabolism and human disease","volume":"71","author":"Gray","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.canlet.2026.218245_bib18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41467-019-13668-3","article-title":"Mitochondrial TCA cycle metabolites control physiology and disease","volume":"11","author":"Martinez-Reyes","year":"2020","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.canlet.2026.218245_bib19","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.cell.2015.07.017","article-title":"Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells","volume":"162","author":"Sullivan","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.canlet.2026.218245_bib20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.molmed.2019.06.009","article-title":"The mitochondrion as an emerging therapeutic target in cancer","volume":"26","author":"Roth","year":"2020","journal-title":"Trends Mol. Med."},{"issue":"5","key":"10.1016\/j.canlet.2026.218245_bib21","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.celrep.2014.04.030","article-title":"Reversible 26S proteasome disassembly upon mitochondrial stress","volume":"7","author":"Livnat-Levanon","year":"2014","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.canlet.2026.218245_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108059","article-title":"Mitochondrial regulation of the 26S proteasome","volume":"32","author":"Meul","year":"2020","journal-title":"Cell Rep."},{"issue":"13","key":"10.1016\/j.canlet.2026.218245_bib23","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","article-title":"The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition","volume":"113","author":"Bianchi","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.canlet.2026.218245_bib24","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.170007","article-title":"Control of mitochondrial biogenesis and function by the ubiquitin-proteasome system","volume":"7","author":"Bragoszewski","year":"2017","journal-title":"Open Biol."},{"issue":"2","key":"10.1016\/j.canlet.2026.218245_bib25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"169","author":"Saxton","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.canlet.2026.218245_bib26","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12964-024-01699-3","article-title":"Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy","volume":"22","author":"Wang","year":"2024","journal-title":"Cell Commun. Signal."},{"issue":"39","key":"10.1016\/j.canlet.2026.218245_bib27","doi-asserted-by":"crossref","first-page":"eabq5575","DOI":"10.1126\/sciadv.abq5575","article-title":"Therapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myeloma","volume":"8","author":"Sharma","year":"2022","journal-title":"Sci. Adv."},{"issue":"23","key":"10.1016\/j.canlet.2026.218245_bib28","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.4502.4502","article-title":"Metformin therapy and survival in multiple myeloma among US veterans with diabetes mellitus","volume":"126","author":"Keller","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.canlet.2026.218245_bib29","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/sj.thj.6200052","article-title":"The 5TMM series: a useful in vivo mouse model of human multiple myeloma","volume":"1","author":"Asosingh","year":"2000","journal-title":"Hematol J"},{"issue":"1","key":"10.1016\/j.canlet.2026.218245_bib30","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1186\/s12885-021-08584-z","article-title":"Correction to: inhibition of mTORC1 through ATF4-induced REDD1 and Sestrin2 expression by Metformin","volume":"21","author":"Jang","year":"2021","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.canlet.2026.218245_bib31","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.tem.2017.07.003","article-title":"Modulation of ATF4-Mediated stress responses in normal and malignant cells","volume":"28","author":"Wortel","year":"2017","journal-title":"Trends Endocrinol. Metabol."},{"issue":"6","key":"10.1016\/j.canlet.2026.218245_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/biom12060756","article-title":"Metformin induces resistance of cancer cells to the proteasome inhibitor Bortezomib","volume":"12","author":"Schlesser","year":"2022","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.canlet.2026.218245_bib33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The warburg effect: how does it benefit cancer cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem. Sci."},{"issue":"9","key":"10.1016\/j.canlet.2026.218245_bib34","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1182\/blood-2010-02-269126","article-title":"Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug","volume":"116","author":"Hu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218245_bib35","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3389\/fonc.2018.00500","article-title":"The influence of metabolism on drug response in cancer","volume":"8","author":"Zaal","year":"2018","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218245_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ph16010111","article-title":"Review on bortezomib resistance in multiple myeloma and potential role of emerging technologies","volume":"16","author":"Kozalak","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.canlet.2026.218245_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1000106","article-title":"Mitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy","volume":"12","author":"Nair","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218245_bib38","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s40164-022-00348-0","article-title":"Targeting the integrated stress response in hematologic malignancies","volume":"11","author":"Nwosu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"issue":"7750","key":"10.1016\/j.canlet.2026.218245_bib39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41586-019-0977-x","article-title":"Breast cancer cells rely on environmental pyruvate to shape the metastatic niche","volume":"568","author":"Elia","year":"2019","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.canlet.2026.218245_bib40","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.cellsig.2015.05.020","article-title":"Pyruvate stimulates mitophagy via PINK1 stabilization","volume":"27","author":"Park","year":"2015","journal-title":"Cell. Signal."},{"issue":"8","key":"10.1016\/j.canlet.2026.218245_bib41","doi-asserted-by":"crossref","first-page":"E1036","DOI":"10.1152\/ajpendo.00151.2012","article-title":"Pyruvate uptake is increased in highly invasive ovarian cancer cells under anoikis conditions for anaplerosis, mitochondrial function, and migration","volume":"303","author":"Caneba","year":"2012","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.canlet.2026.218245_bib42","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.neo.2019.04.007","article-title":"Determination of Pyruvate Metabolic fates modulates head and neck tumorigenesis","volume":"21","author":"Chen","year":"2019","journal-title":"Neoplasia"},{"issue":"8","key":"10.1016\/j.canlet.2026.218245_bib43","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1038\/bjc.2013.120","article-title":"Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib","volume":"108","author":"Sanchez","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2026.218245_bib44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.freeradbiomed.2011.03.031","article-title":"Ubiquitin-proteasome pathway and cellular responses to oxidative stress","volume":"51","author":"Shang","year":"2011","journal-title":"Free Radic. Biol. Med."},{"issue":"5","key":"10.1016\/j.canlet.2026.218245_bib45","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M110.006924","article-title":"Oxidative stress-mediated regulation of proteasome complexes","volume":"10","author":"Aiken","year":"2011","journal-title":"Mol. Cell. Proteomics"},{"issue":"3","key":"10.1016\/j.canlet.2026.218245_bib46","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrendo.2013.256","article-title":"Metformin--mode of action and clinical implications for diabetes and cancer","volume":"10","author":"Pernicova","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.canlet.2026.218245_bib47","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3389\/fendo.2018.00753","article-title":"Metformin-induced mitochondrial complex I inhibition: facts, uncertainties, and consequences","volume":"9","author":"Fontaine","year":"2018","journal-title":"Front. Endocrinol."},{"issue":"2","key":"10.1016\/j.canlet.2026.218245_bib48","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/path.6066","article-title":"Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis","volume":"260","author":"Van der Vreken","year":"2023","journal-title":"J. Pathol."},{"issue":"2","key":"10.1016\/j.canlet.2026.218245_bib49","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1242\/dmm.008110","article-title":"Metformin differentially activates ER stress signaling pathways without inducing apoptosis","volume":"5","author":"Quentin","year":"2012","journal-title":"Dis. Model. Mech."},{"issue":"11","key":"10.1016\/j.canlet.2026.218245_bib50","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1038\/leu.2015.157","article-title":"Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib","volume":"29","author":"Jagannathan","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.canlet.2026.218245_bib51","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13046-018-0731-5","article-title":"Metformin induces autophagy and G0\/G1 phase cell cycle arrest in myeloma by targeting the AMPK\/mTORC1 and mTORC2 pathways","volume":"37","author":"Wang","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.canlet.2026.218245_bib52","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1158\/0008-5472.CAN-14-3400","article-title":"Metabolic signature identifies novel targets for drug resistance in multiple myeloma","volume":"75","author":"Maiso","year":"2015","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.canlet.2026.218245_bib53","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1535370217743919","article-title":"Pyruvate enhancement of cardiac performance: cellular mechanisms and clinical application","volume":"243","author":"Mallet","year":"2018","journal-title":"Exp. Biol. Med."},{"issue":"1","key":"10.1016\/j.canlet.2026.218245_bib54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1001\/jamaophthalmol.2021.4576","article-title":"Nicotinamide and pyruvate for neuroenhancement in open-angle glaucoma: a phase 2 randomized clinical trial","volume":"140","author":"De Moraes","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.canlet.2026.218245_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123125","article-title":"Bortezomib in cancer therapy: mechanisms, side effects, and future proteasome inhibitors","volume":"358","author":"Sogbein","year":"2024","journal-title":"Life Sci."},{"issue":"12","key":"10.1016\/j.canlet.2026.218245_bib56","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/17460441.2019.1660642","article-title":"Estimating human ADME properties, pharmacokinetic parameters and likely clinical dose in drug discovery","volume":"14","author":"Lucas","year":"2019","journal-title":"Expet Opin. Drug Discov."},{"issue":"6","key":"10.1016\/j.canlet.2026.218245_bib57","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1080\/10428194.2017.1365859","article-title":"Managing multiple myeloma in elderly patients","volume":"59","author":"Diamond","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.canlet.2026.218245_bib58","article-title":"Targeting metabolic pathways alleviates bortezomib-induced neuropathic pain without compromising anticancer efficacy in a sex-specific manner","volume":"5","author":"Kuppusamy","year":"2024","journal-title":"Front Pain Res (Lausanne)"},{"issue":"7","key":"10.1016\/j.canlet.2026.218245_bib59","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1182\/blood-2018-06-858415","article-title":"Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin","volume":"133","author":"Efentakis","year":"2019","journal-title":"Blood"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352600008X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352600008X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:09:07Z","timestamp":1779116947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438352600008X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":59,"alternative-id":["S030438352600008X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218245","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The clinically available supplement pyruvate enhances the therapeutic effect of bortezomib in Multiple Myeloma by modulating mitochondrial metabolism","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218245","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218245"}}